Clinical Trial Update: Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT [Phase 3]

View source ↗

Summary

Phase 3 study evaluating etamsylate to prevent bleeding versus placebo in patients undergoing hematopoietic stem cell transplantation; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• Etamsylate (ethamsylate)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Hematopoietic Stem Cell Transplantation, Thrombocytopenia | Phase 3 | Status: RECRUITING